These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30211927)

  • 1. Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation - Messages from the 2018 EHRA.
    Tomaszuk-Kazberuk A; Kołtowski L; Balsam P; Koziński M; Kapłon-Cieślicka A; Kupczyńska K; Domienik-Karłowicz J; Budaj-Fidecka A; Buszman P; Wybraniec M; Burchardt P; Michalski B; Jaguszewski MJ
    Cardiol J; 2018; 25(4):423-440. PubMed ID: 30211927
    [No Abstract]   [Full Text] [Related]  

  • 2. NOACs only for those who cannot tolerate a VKA: where is the evidence?
    Bhagirath VC; Cosyns B; Eikelboom JW
    Acta Cardiol; 2019 Feb; 74(1):17-20. PubMed ID: 29475399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
    Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
    Europace; 2015 Oct; 17(10):1467-507. PubMed ID: 26324838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.
    Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Georg Haeusler K; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
    Europace; 2018 Aug; 20(8):1231-1242. PubMed ID: 29562331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients.
    Dillinger JG; Aleil B; Cheggour S; Benhamou Y; Béjot Y; Marechaux S; Delluc A; Bertoletti L; Lellouche N
    Arch Cardiovasc Dis; 2018 Feb; 111(2):85-94. PubMed ID: 28988597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation.
    Rivera-Caravaca JM; Esteve-Pastor MA; Roldán V; Marín F; Lip GYH
    Expert Opin Drug Saf; 2017 Sep; 16(9):1051-1062. PubMed ID: 28678553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey.
    Lip GY; Bongiorni MG; Dobreanu D; Lewalter T; Hastrup Svendsen J; Blomström-Lundqvist C;
    Europace; 2013 Oct; 15(10):1526-32. PubMed ID: 24072770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Arithmetic of non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation].
    Rubboli A; Vecchio S
    G Ital Cardiol (Rome); 2020 Jul; 21(7):564. PubMed ID: 32555577
    [No Abstract]   [Full Text] [Related]  

  • 9. New oral anticoagulants: a practical guide for physicians.
    Hinojar R; Jiménez-Natcher JJ; Fernández-Golfín C; Zamorano JL
    Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):134-45. PubMed ID: 27533984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent ischemic stroke in atrial fibrillation with non-vitamin K antagonist oral anticoagulation.
    Woo HG; Chung I; Gwak DS; Kim BK; Kim BJ; Bae HJ; Han MK
    J Clin Neurosci; 2019 Jun; 64():127-133. PubMed ID: 30929960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Vitamin K Antagonist Oral Anticoagulants: The Clinician's New Challenge.
    Yorkgitis BK; Zhang J; Rappold JF
    J Am Osteopath Assoc; 2015 Oct; 115(10):612-21. PubMed ID: 26414714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
    Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of 'valvular' atrial fibrillation: results of the European Heart Rhythm Association Survey.
    Potpara TS; Lip GY; Larsen TB; Madrid A; Dobreanu D; Jędrzejczyk-Patej E; Dagres N;
    Europace; 2016 Oct; 18(10):1593-1598. PubMed ID: 27876696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
    Bennaghmouch N; de Veer AJWM; Bode K; Mahmoodi BK; Dewilde WJM; Lip GYH; Brueckmann M; Kleine E; Ten Berg JM
    Circulation; 2018 Mar; 137(11):1117-1129. PubMed ID: 29101289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists.
    Konieczyńska M; Sobieraj E; Bryk AH; Dębski M; Polak M; Podolec P; Małecka B; Pająk A; Desteghe L; Heidbuchel H; Undas A
    Kardiol Pol; 2018; 76(7):1089-1096. PubMed ID: 29528483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association.
    Hernández Madrid A; Potpara TS; Dagres N; Chen J; Larsen TB; Estner H; Todd D; Bongiorni MG; Sciaraffia E; Proclemer A; Cheggour S; Amara W; Blomstrom-Lundqvist C
    Europace; 2016 Mar; 18(3):463-7. PubMed ID: 26899998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
    Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
    Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.